Johnson & Johnson Innovation - JJDC’s Neuropace NPCE Stock Holding History

Johnson & Johnson Innovation - JJDC’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$1.32M	Buy	+55,435	New	+$1.29M	0.13%	15

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's NPCE Position: Q2 2021 in Review

Johnson & Johnson Innovation - JJDC opened a new position in Neuropace (NPCE) in Q2 2021: 55,435 shares worth $1.32M. The stake represents 0.13% of the portfolio and ranks #15 among its holdings.

44 funds tracked by Wall St. Rank hold NPCE as of Q2 2021.

Johnson & Johnson Innovation - JJDC held 55,435 shares of Neuropace worth $1.32M as of Q2 2021.
Neuropace was a new Johnson & Johnson Innovation - JJDC position in Q2 2021.
Neuropace made up 0.13% of Johnson & Johnson Innovation - JJDC's portfolio in Q2 2021, its #15 holding.
44 funds tracked by Wall St. Rank held Neuropace as of Q2 2021.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q2 2021, filed 3 Aug 2021.